GSK stock gains support from licensing deal and solid first-half growth

Published on 09/04/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock trades near recent highs as investors digest a new licensing deal for an experimental oncology drug and solid first-half 2026 revenue growth. The shares remain a key pharmaceutical blue chip for London investors.

3D-Architekturrender eines modernen Glas-Bürogebäudes mit Grünflächen davor — GSK plc (ISIN GB0009252882) präsentiert sich im Architektur-Render als moderner Firmensitz mit Glasfassade und Grünanlage, Illustration mit AI erstellt.

GSK (ISIN GB0009252882) stock is trading around 1,866.50 pence on the London Stock Exchange as of September 3, 2026, according to a quote overview, implying a modest gain of about 2.3% over a recent reference period as the market absorbs fresh pipeline and earnings news. For investors, the combination of steady top-line growth in the first half of 2026 and a new oncology licensing deal provides a tangible backdrop for the current valuation.

Pipeline deal underscores oncology ambitions

According to a news update summarizing Hong Kong warrant market data on September 4, 2026, a subsidiary of GSK has entered into an exclusive development and license agreement with HUTCHMED for the experimental solid-tumor drug candidate HMPL-A830, granting GSK rights outside Mainland China, Hong Kong, Macau and Taiwan. The agreement gives GSK global rights for this first-in-class KRAS-EGFR antibody-drug conjugate in most major markets, reinforcing the company’s push to broaden its oncology portfolio.

The cooperation structure means GSK will take responsibility for development and commercialization in its territories, while HUTCHMED retains rights in China-related markets and will benefit from milestones and potential royalties, as described in the transaction announcement. For shareholders, the deal suggests that GSK is willing to commit capital and development resources to targeted therapies that could drive medium-term revenue growth if the program succeeds in late-stage trials.

Earnings picture: first-half 2026 revenue and profit growth

Market data compiled by a financial analytics platform focusing on GSK’s fundamentals shows that the company reported revenue of 16,038 million GBP for the first half of 2026, up from 15,502 million GBP in the first half of 2025, representing an increase of 3.46%. The same dataset indicates that operating profit, measured as EBIT, rose from 5,164 million GBP in the first half of 2025 to 5,450 million GBP in the first half of 2026, a gain of 5.54%. These figures underline that GSK is not only expanding sales but also improving profitability at the operating level.

The quarterly breakdown embedded in the same financial overview highlights that GSK generated revenue of 8,409 million GBP in the first quarter of 2026 and 8,899 million GBP in the second quarter of 2026, with each quarter modestly ahead of the respective consensus forecasts that had been compiled before the results. For example, the first quarter 2026 revenue of 8,409 million GBP compared with an analyst expectation of 8,247 million GBP, implying a positive surprise of 1.97%, while second quarter 2026 revenue of 8,899 million GBP was above the forecast of 8,745 million GBP, a beat of 1.76%. This pattern of small but consistent beats helps support investor confidence that GSK can execute on its guidance.

Go deeper

More GSK stock coverage and data

Readers who want to track GSK stock developments and regulatory disclosures can find additional background, figures and news in the thematic overview and on the company’s investor relations pages.

All news on GSK stock Investor Relations

Key product focus: vaccine and specialty medicines portfolio

Beyond individual licensing deals, GSK’s growth strategy rests on a diversified portfolio of vaccines and specialty medicines in respiratory, HIV, immunology and oncology. The same financial datasets that summarize first-half 2026 performance point to steady contributions from vaccines and specialty medicines, which together account for a significant share of total revenue, even though the exact segment split is not fully detailed in the recent overview. For retail investors, this mix means that the company is less dependent on any single blockbuster and can balance patent cycles with new launches.

GSK stock valuation and price context

A stock analysis page focused on GSK indicates that the shares are quoted at around 1,866.50 pence, with the recent session showing a small move of about negative 0.08%, as of an early September 2026 snapshot. The same page notes that GSK shares have increased by approximately 2.3% over a defined comparison period, suggesting that the stock has edged higher in recent weeks but remains far from any speculative spike. For investors comparing GSK with broader indices, the moderate gain illustrates that the stock has been a steady rather than volatile performer during this phase.